Free tool
FAERS Monitor: Trazimera
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761081 or its brand name (Trazimera, Trastuzumab-Qyyp). Reports on generic versions are filed under their own applications.
Reports
390
Serious
292
75% of reports
Hospitalization
70
Death reported
42
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea49
- off label use43
- chills34
- diarrhoea33
- dyspnoea33
- fatigue31
- headache31
- infusion related reaction31
- pruritus28
- weight decreased27
- death25
- vomiting25
- malaise22
- weight increased21
- pain20
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2019 | 3 |
| 2020 | 29 |
| 2021 | 54 |
| 2022 | 59 |
| 2023 | 85 |
| 2024 | 90 |
| 2025 | 50 |
| 2026 | 19 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,769 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion related reactionSignal | 31 | 25.2 | 18.0 | 699 |
| chillsSignal | 34 | 15.6 | 11.3 | 454 |
| weight decreasedSignal | 27 | 5.2 | 3.6 | 89 |
| weight increasedSignal | 21 | 5.1 | 3.3 | 65 |
| pruritusSignal | 28 | 3.9 | 2.8 | 59 |
| nauseaSignal | 49 | 3.3 | 2.6 | 81 |
| dyspnoeaSignal | 33 | 3.1 | 2.3 | 47 |
| vomitingSignal | 25 | 2.9 | 2.0 | 29 |
| diarrhoeaSignal | 33 | 2.8 | 2.0 | 36 |
| malaiseSignal | 22 | 2.7 | 1.8 | 22 |
| headacheSignal | 31 | 2.7 | 1.9 | 32 |
| off label useSignal | 43 | 2.6 | 2.0 | 44 |
| fatigueSignal | 31 | 2.1 | 1.5 | 19 |
| pain | 20 | 1.8 | 1.1 | 6 |
| death | 25 | 1.6 | 1.1 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.